Zentalis Pharmaceuticals, Inc. (ZNTL) Return on equity 2022–2025
Zentalis Pharmaceuticals, Inc. (ZNTL) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-63.4%FY2025 · since FY2022: -54.6% → -63.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -63.4% | -14.2 pp |
| FY2024 | -49.2% | +17.6 pp |
| FY2023 | -66.8% | -12.2 pp |
| FY2022 | -54.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ZNTL financial trends
ZNTL RevenueZNTL Net incomeZNTL Net marginZNTL Gross profitZNTL Gross marginZNTL Operating incomeZNTL Operating marginZNTL Operating cash flowZNTL Free cash flowZNTL Capital expendituresZNTL Stock buybacksZNTL Dividends paidZNTL Total assetsZNTL Total liabilitiesZNTL Shareholders’ equityZNTL overview →